$23 First Aid Only 90753 25 Person Contractor ANSI A+ First Aid Kit Health Household Health Care First Aid ANSI,Aid,Only,A+,Kit,kccentre.com,Person,25,Health Household , Health Care , First Aid,/Feme391777.html,Contractor,$23,90753,First,First,Aid ANSI,Aid,Only,A+,Kit,kccentre.com,Person,25,Health Household , Health Care , First Aid,/Feme391777.html,Contractor,$23,90753,First,First,Aid First Max 59% OFF Aid Only 90753 25 Contractor ANSI Person Kit A+ $23 First Aid Only 90753 25 Person Contractor ANSI A+ First Aid Kit Health Household Health Care First Aid First Max 59% OFF Aid Only 90753 25 Contractor ANSI Person Kit A+

First Max 59% OFF Aid Only 90753 25 Contractor Max 68% OFF ANSI Person Kit A+

First Aid Only 90753 25 Person Contractor ANSI A+ First Aid Kit

$23

First Aid Only 90753 25 Person Contractor ANSI A+ First Aid Kit

|||

Product description

The 25 Person ANSI A+ Type III Contractor First Aid Kit in the plastic carrying case contains 126 pieces to treat on the job injuries. The contents of this kit exceed the 2015 ANSI Class A requirements . The weatherproof storage case has two latches to keep the case closed and a handle to facilitate transportation to the site of an injury. The case also includes mounting holes in the handle for mounting the case on a wall or other flat vertical surface.


From the manufacturer

9300-10P 90670 90753 9301-25P 9301-25M 90671
Meets OSHA Regulations ✓ ✓ ✓ ✓ ✓ ✓
Meets ANSI Standards ✓ ✓
Number of People 10 25 25 25 25 50
Piece Count 95 180 126 178 178 252
Case Material Plastic Metal Plastic Plastic Metal Metal
Includes Medications
Industry Specific Contractor Contractor Contractor Contractor Contractor Contractor

First Aid Only 90753 25 Person Contractor ANSI A+ First Aid Kit

CURRENT ISSUE
September, 2021

No. 106 (9)

2020 Impact Factor: 9.941 Submission > Acceptance: 52 days
ARTICLES IN THREE SENTENCES
Article

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

This open-label, single-arm study investigated the long-term efficacy of tafasitamab plus lenalidomide in 81 patients with relapsed/refractory diffuse large B-cell lymphoma. The response rate was 57.5%, including complete responses in 40.0% of patients, and the median duration of response was 43.9 months. This treatment is a valuable option for patients not eligible for autologous stem-cell transplantation.

Johannes Duell et al.

Case Report

Clinical genomic profiling of novel grey zone lymphoma paired lesions with sequential central nervous system involvement in two adolescent patients

Grey zone lymphoma is a B-cell lymphoma, unclassifiable, with features intermediate between those of large B-cell lymphoma and classic Hodgkin lymphoma. The in-depth study of the two adolescent patients described in this case report expands the clinicopathological and genomic spectrum of this rare pediatric disease. Moreover, it provides information on their response to treatment.

Cagla Y. Benkli et al.

Article

CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients

The clinical picture of 56 patients with congenital amegakaryocytic thrombocytopenia due to MPL mutations was much more varied than previously thought. Twenty-five per cent of them had no signs of thrombocytopenia at birth, and 50% had non-hematologic defects. Pancytopenia developed in (nearly) all patients and hematopoietic stem-cell transplantation was effective in 87% of cases.

Manuela Germeshausen et al.

Article

Oxidative stress activates red cell adhesion to laminin in sickle cell disease

Sickle red blood cells exhibit abnormal adhesion to laminin mediated by Lu/BCAM protein at their surface. This study provides evidence of the involvement of oxidative stress in post-translational modifications of Lu/BCAM which impact the protein’s distribution and cis-interaction with glycophorin C at the cell surface activating its adhesive function in dense sickle red cells. The authors speculate that antioxidant drugs might attenuate this phenomenon.

Maria Alejandra Lizarralde-Iragorri et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA